Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. https://www.nature.com/articles/s41388-018-0522-7 de Boer HR, Pool M, Joosten E, Everts M, Samplonius DF, Helfrich W, Groen HJM, van Cooten S, Fusetti F, Fehrmann RSN, de Vries EGE, van Vugt MATM Abstract Tumor responses to cancer therapeutics are generally monitored every 2-3 months based on…
TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. https://www.nature.com/articles/s41388-018-0470-2 van Gijn SE, Wierenga E, van den Tempel N, Kok YP, Heijink AM, Spierings DCJ, Foijer F, van Vugt MATM, Fehrmann RSN Abstract Genomic instability is a hallmark feature of cancer cells, and can be caused by defective DNA repair,…
Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. https://www.cancertreatmentreviews.com/article/S0305-7372(18)30134-8/fulltext Rico D. Bense, Si-Qi Qiu, Elisabeth G.E. de Vries, Carolien P. Schröder, Rudolf S.N. Fehrmann Abstract Extended endocrine therapy can reduce recurrences occurring more than 5 years after diagnosis (late recurrences) in estrogen receptor (ER)-positive breast cancer. Given…
Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database. Am J Pathol. 2018 Jun 20. pii: S0002-9440(18)30129-9. doi: 10.1016/j.ajpath.2018.05.014. Moek KL, Fehrmann RSN, van der Vegt B, de Vries EGE, de Groot DJA. Abstract Glypican 3 (GPC3), a membrane-bound heparan sulfate proteoglycan, is…
Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma. Clin Cancer Res. 2018 Apr 23. pii: clincanres.3060.2017. doi: 10.1158/1078-0432.CCR-17-3060. Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen A, Duiker EW, Weening D, Itamochi H, Kluin RJ, Reyners AKL, Birrer MJ, Salvesen…
Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma. Oral Oncology 2018; 80:33-39 Saskia H. Hanemaaijer, Stephanie E. van Gijn, Sjoukje F. Oosting, Boudewijn E.C. Plaat, Kirsten L. Moek, Ed M. Schuuring, Bernard F.A.M. van der Laan, Jan L.N. Roodenburg, Marcel A.T.M. van Vugt, Bert van der Vegt, Rudolf S.N. Fehrmann…
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. PLoS One. 2018 Feb 28;13(2):e0193098. doi: 10.1371/journal.pone.0193098. eCollection 2018. de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt M, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN#, van Meerten T#.…
The antibody-drug conjugate target landscape across a broad range of tumour types made it to the cover of Annals of Oncology. Annals of Oncology, mdx541, https://doi.org/10.1093/annonc/mdx541 K.L. Moek D.J.A. de Groot E.G.E. de Vries R.S.N. Fehrmann
Data driven prioritization and review of targets for molecular based theranostic approaches in pancreatic cancer. J Nucl Med. 2017 Oct 19. pii: jnumed.117.198440. doi: 10.2967/jnumed.117.198440. [Epub ahead of print] # contributed equally Koller M, Hartmans E, de Groot DJA, Zhao XJ, van Dam GM, Nagengast WB#, Fehrmann RSN# Molecular targeted therapeutical and imaging strategies directed…
Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. ESMO Open; DOI: 10.1136/esmoopen-2017-000272 Sjoukje F Oosting, Rudolf S Fehrmann, Elisabeth G E de Vries In the Oxford dictionary, ‘Independent’ is defined as ‘Free from outside control; not subject to another’s authority’. Independence can be critical to identify important issues for patients. The…